Literature DB >> 9593048

Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides.

J E Gee1, I Robbins, A C van der Laan, J H van Boom, C Colombier, M Leng, A M Raible, J S Nelson, B Lebleu.   

Abstract

Antisense oligonucleotides (ONs) are designed to hybridize target mRNA in a sequence-specific manner and inhibit gene expression by preventing translation, either by activation of RNase H or steric blockage of the ribosome complex. Second-generation ONs, which possess greater binding affinity for target RNA relative to the isosequential phosphodiester (PO) ONs, have been developed and include, among others, peptide nucleic acids (PNA) and N3' P5' phosphoramidate oligonucleotides (npONs). In the present study, PNA and npON derivatives were targeted to the coding portion of the complementary mRNA of the N protein of the vesicular stomatitis virus (VSV) in order to evaluate their ability to arrest translation in an in vitro rabbit reticulocyte lysate system. High-affinity hybridization of ONs lacking RNase H activity was not sufficient to block translation in this test system. Only antisense ONs acting via an RNase H mechanism or by steric hindrance through covalent attachment (via transplatin modification) to the target mRNA were found to definitively arrest translation in this study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593048     DOI: 10.1089/oli.1.1998.8.103

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  8 in total

1.  Inhibition of IL-6 in mice by anti-NF-kappaB oligodeoxyribonucleotide N3'-->oligodeoxyribonnucleotide N3' --> P5' phosphoramidates.

Authors:  L Wang; S Gryaznov; M Nerenberg
Journal:  Inflammation       Date:  1999-12       Impact factor: 4.092

2.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

3.  Inhibition of in vitro and ex vivo translation by a transplatin-modified oligo(2'-O-methylribonucleotide) directed against the HIV-1 gag-pol frameshift signal.

Authors:  K Aupeix-Scheidler; S Chabas; L Bidou; J P Rousset; M Leng; J J Toulmé
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

4.  Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.

Authors:  J B Opalinska; A Kalota; Lida K Gifford; Ponzy Lu; Kuang-Yu Jen; P I Pradeepkumar; J Barman; T K Kim; C R Swider; J Chattopadhyaya; A M Gewirtz
Journal:  Nucleic Acids Res       Date:  2004-10-28       Impact factor: 16.971

Review 5.  Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.

Authors:  Andre Cassell; Jennifer R Grandis
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

6.  Biophysical studies on the stability of DNA intrastrand cross-links of transplatin.

Authors:  Jana Kasparkova; Victoria Marini; Vendula Bursova; Viktor Brabec
Journal:  Biophys J       Date:  2008-08-01       Impact factor: 4.033

7.  Identification and characterization of high affinity antisense PNAs for the human unr (upstream of N-ras) mRNA which is uniquely overexpressed in MCF-7 breast cancer cells.

Authors:  Huafeng Fang; Xuan Yue; Xiaoxu Li; John-Stephen Taylor
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

8.  The preparation of new phosphorus-centered functional groups for modified oligonucleotides and other natural phosphates.

Authors:  Arnaud Gautier; Chrystel Lopin; Goulnara Garipova; Olivier Dubert; Irina Kalinina; Carmen Salcedo; Sébastien Balieu; Stéphane Glatigny; Jean-Yves Valnot; Géraldine Gouhier; Serge R Piettre
Journal:  Molecules       Date:  2005-09-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.